Predictors of ETP resistance to TM
| Variable . | Univariate analysis . | Multivariate analysis . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Quantitative model (P < .0001) . | Qualitative model (P < .0001) . | ||||||||||
| cOR . | 95% CI . | P value . | aOR . | 95% CI . | P value . | RC . | aOR . | 95% CI . | P value . | RC . | |
| Age | 0.969 | 0.961-0.976 | <.0001 | 0.976 | 0.951-1.001 | .0600 | −0.025 | ||||
| Age <35 y | 2.224 | 1.177-2.951 | <.0001 | 2.094 | 0.864-5.079 | .1020 | 0.739 | ||||
| VTE:PE | 1.117 | 0.862-1.447 | .4025 | ||||||||
| Male gender | 0.228 | 0.162-0.322 | <.0001 | 0.462 | 0.195-1.092 | .0786 | −0.772 | 0.474 | 0.218-1.032 | .0600 | −0.747 |
| Family history of VTE | 1.101 | 0.527-2.304 | .794 | ||||||||
| Fibrinogen, g/L | 1.096 | 0.806-1.491 | .559 | ||||||||
| Fibrinogen >4 g/L | 1.015 | 0.563-1.830 | .959 | ||||||||
| D-di, mg/L | 4.807 | 2.200-10.50 | <.0001 | 4.079 | 1.407-11.819 | .0096 | 1.406 | ||||
| D-di >0.5 mg/L | 2.217 | 1.704-2.885 | <.0001 | ||||||||
| D-di >age-adjusted limit | 2.794 | 2.137-3.653 | <.0001 | 3.065 | 1.326-7.085 | .0088 | 1.120 | ||||
| FXI | 0.991 | 0.982-1.001 | .0727 | ||||||||
| FXI >120 IU/L | 0.645 | 0.387-1.054 | .0796 | ||||||||
| FXI >130 IU/L | 0.653 | 0.314-1.095 | .1046 | ||||||||
| FIX | 0.987 | 0.973-1.095 | .0732 | ||||||||
| FIX >129 IU/L | 0.712 | 0.431-1.178 | .1867 | ||||||||
| FIX >138 IU/L | 0.537 | 0.287-1.119 | .0819 | 0.349 | 0.114-1.063 | .0640 | −1.054 | ||||
| FVIII | 1.003 | 0.999-1.007 | .1436 | ||||||||
| FVIII >150 IU/L | 2.261 | 1.132-4.516 | .0208 | 2.680 | 1.180-6.089 | .0185 | 0.986 | ||||
| FVIII >234 IU/L | 1.742 | 0.774-3.918 | .1797 | ||||||||
| Positive LA | 3.508 | 1.779-6.917 | .0003 | ||||||||
| Rosner index | 1.064 | 1.015-1.115 | .0098 | 0.915 | 0.863-0.971 | .0033 | −0.089 | ||||
| DRVVT ratio | 7.476 | 1.727-32.36 | .0071 | ||||||||
| aCL-IgG, GPL units | 1.008 | 0.969-1.048 | .686 | ||||||||
| Positive aCL-IgG | 1.224 | 0.654-2.291 | .528 | ||||||||
| aCL-IgM, MPL units | 1.046 | 0.740-2.596 | .508 | ||||||||
| Positive aCL-IgM | 1.218 | 0.555-2.639 | .632 | ||||||||
| ab2Gp1 IgG, U | 1.007 | 0.982-1.033 | .579 | ||||||||
| Positive ab2Gp1 IgG | 1.340 | 0.707-2.544 | .369 | ||||||||
| ab2Gp1 IgM, U | 1.059 | 0.444-2.421 | .698 | ||||||||
| Positive ab2Gp1 IgM | 1.381 | 0.714-2.674 | .337 | ||||||||
| AT, IU/L | 0.965 | 0.944-0.987 | .0018 | 0.977 | 0.944-1.011 | .1897 | −0.023 | ||||
| AT <80 IU/L | 11.72 | 1.35-101.9 | .0256 | ||||||||
| AT <70 IU/L | 6.876 | 0.705-67.0 | .097 | ||||||||
| PC, IU/L | 0.982 | 0.973-0.991 | .0025 | ||||||||
| PC <65 IU/L | 10.93 | 2.316-51.58 | .0025 | 15.270 | 1.216-191.8 | .0347 | 2.726 | ||||
| PS, IU/L | 0.949 | 0.93-0.962 | <.0001 | 0.954 | 0.936-0.973 | <.0001 | −0.047 | ||||
| PS <60 IU/L | 8.418 | 4.533-15.63 | <.0001 | ||||||||
| PS <50 IU/L | 11.13 | 5.098-24.29 | <.0001 | 3.824 | 1.107-13.207 | .0339 | 1.341 | ||||
| PS <40 IU/L | 9.479 | 3.344-26.17 | <.0001 | ||||||||
| PS <35 IU/L | 18.15 | 4.068-80.93 | .0001 | ||||||||
| F5 rs6025-positive | 0.799 | 0.316-2.021 | .636 | ||||||||
| FII IU/L | 0.975 | 0.943-1.009 | .1455 | ||||||||
| FII >115 IU/L | 0.492 | 0.153-1.583 | .234 | ||||||||
| F2 rs1799963-positive | 0.593 | 0.240-1.456 | .254 | ||||||||
| Variable . | Univariate analysis . | Multivariate analysis . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Quantitative model (P < .0001) . | Qualitative model (P < .0001) . | ||||||||||
| cOR . | 95% CI . | P value . | aOR . | 95% CI . | P value . | RC . | aOR . | 95% CI . | P value . | RC . | |
| Age | 0.969 | 0.961-0.976 | <.0001 | 0.976 | 0.951-1.001 | .0600 | −0.025 | ||||
| Age <35 y | 2.224 | 1.177-2.951 | <.0001 | 2.094 | 0.864-5.079 | .1020 | 0.739 | ||||
| VTE:PE | 1.117 | 0.862-1.447 | .4025 | ||||||||
| Male gender | 0.228 | 0.162-0.322 | <.0001 | 0.462 | 0.195-1.092 | .0786 | −0.772 | 0.474 | 0.218-1.032 | .0600 | −0.747 |
| Family history of VTE | 1.101 | 0.527-2.304 | .794 | ||||||||
| Fibrinogen, g/L | 1.096 | 0.806-1.491 | .559 | ||||||||
| Fibrinogen >4 g/L | 1.015 | 0.563-1.830 | .959 | ||||||||
| D-di, mg/L | 4.807 | 2.200-10.50 | <.0001 | 4.079 | 1.407-11.819 | .0096 | 1.406 | ||||
| D-di >0.5 mg/L | 2.217 | 1.704-2.885 | <.0001 | ||||||||
| D-di >age-adjusted limit | 2.794 | 2.137-3.653 | <.0001 | 3.065 | 1.326-7.085 | .0088 | 1.120 | ||||
| FXI | 0.991 | 0.982-1.001 | .0727 | ||||||||
| FXI >120 IU/L | 0.645 | 0.387-1.054 | .0796 | ||||||||
| FXI >130 IU/L | 0.653 | 0.314-1.095 | .1046 | ||||||||
| FIX | 0.987 | 0.973-1.095 | .0732 | ||||||||
| FIX >129 IU/L | 0.712 | 0.431-1.178 | .1867 | ||||||||
| FIX >138 IU/L | 0.537 | 0.287-1.119 | .0819 | 0.349 | 0.114-1.063 | .0640 | −1.054 | ||||
| FVIII | 1.003 | 0.999-1.007 | .1436 | ||||||||
| FVIII >150 IU/L | 2.261 | 1.132-4.516 | .0208 | 2.680 | 1.180-6.089 | .0185 | 0.986 | ||||
| FVIII >234 IU/L | 1.742 | 0.774-3.918 | .1797 | ||||||||
| Positive LA | 3.508 | 1.779-6.917 | .0003 | ||||||||
| Rosner index | 1.064 | 1.015-1.115 | .0098 | 0.915 | 0.863-0.971 | .0033 | −0.089 | ||||
| DRVVT ratio | 7.476 | 1.727-32.36 | .0071 | ||||||||
| aCL-IgG, GPL units | 1.008 | 0.969-1.048 | .686 | ||||||||
| Positive aCL-IgG | 1.224 | 0.654-2.291 | .528 | ||||||||
| aCL-IgM, MPL units | 1.046 | 0.740-2.596 | .508 | ||||||||
| Positive aCL-IgM | 1.218 | 0.555-2.639 | .632 | ||||||||
| ab2Gp1 IgG, U | 1.007 | 0.982-1.033 | .579 | ||||||||
| Positive ab2Gp1 IgG | 1.340 | 0.707-2.544 | .369 | ||||||||
| ab2Gp1 IgM, U | 1.059 | 0.444-2.421 | .698 | ||||||||
| Positive ab2Gp1 IgM | 1.381 | 0.714-2.674 | .337 | ||||||||
| AT, IU/L | 0.965 | 0.944-0.987 | .0018 | 0.977 | 0.944-1.011 | .1897 | −0.023 | ||||
| AT <80 IU/L | 11.72 | 1.35-101.9 | .0256 | ||||||||
| AT <70 IU/L | 6.876 | 0.705-67.0 | .097 | ||||||||
| PC, IU/L | 0.982 | 0.973-0.991 | .0025 | ||||||||
| PC <65 IU/L | 10.93 | 2.316-51.58 | .0025 | 15.270 | 1.216-191.8 | .0347 | 2.726 | ||||
| PS, IU/L | 0.949 | 0.93-0.962 | <.0001 | 0.954 | 0.936-0.973 | <.0001 | −0.047 | ||||
| PS <60 IU/L | 8.418 | 4.533-15.63 | <.0001 | ||||||||
| PS <50 IU/L | 11.13 | 5.098-24.29 | <.0001 | 3.824 | 1.107-13.207 | .0339 | 1.341 | ||||
| PS <40 IU/L | 9.479 | 3.344-26.17 | <.0001 | ||||||||
| PS <35 IU/L | 18.15 | 4.068-80.93 | .0001 | ||||||||
| F5 rs6025-positive | 0.799 | 0.316-2.021 | .636 | ||||||||
| FII IU/L | 0.975 | 0.943-1.009 | .1455 | ||||||||
| FII >115 IU/L | 0.492 | 0.153-1.583 | .234 | ||||||||
| F2 rs1799963-positive | 0.593 | 0.240-1.456 | .254 | ||||||||
ab2Gp1 IgG, anti-β2-glycoprotein I IgG; acL-IgG, anticardiolipin immunoglobulin G; aOR, adjusted odds ratio (adjustment on all finally retained variables in the model); AT, antithrombin; CI, confidence interval; cOR, crude odds ratio; D-di, D-dimers; DRVVT, dilute Russell’s viper venom time; FII, coagulation factor II; FIX, coagulation factor IX; FXI, coagulation factor XI; PC, protein C; PE, pulmonary embolism; PS, protein S; RC, estimated multivariate regression coefficient.